Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-244X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial ; volume:16 ; number:1 ; day:29 ; month:5 ; year:2016 ; pages:1-8 ; date:12.2016
BMC psychiatry ; 16, Heft 1 (29.5.2016), 1-8, 12.2016
- Creator
-
Takekita, Yoshiteru
- Contributor
-
Koshikawa, Yosuke
Fabbri, Chiara
Sakai, Shiho
Sunada, Naotaka
Onohara, Ai
Nishida, Keiichiro
Yoshimura, Masafumi
Kato, Masaki
Serretti, Alessandro
Kinoshita, Toshihiko
SpringerLink (Online service)
- DOI
-
10.1186/s12888-016-0883-9
- URN
-
urn:nbn:de:1111-201606018445
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Takekita, Yoshiteru
- Koshikawa, Yosuke
- Fabbri, Chiara
- Sakai, Shiho
- Sunada, Naotaka
- Onohara, Ai
- Nishida, Keiichiro
- Yoshimura, Masafumi
- Kato, Masaki
- Serretti, Alessandro
- Kinoshita, Toshihiko
- SpringerLink (Online service)
Other Objects (12)
Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Long-Acting Reversible Contraception
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Development of long-acting ARV’s
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia
Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Long-Acting Reversible Contraception
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Development of long-acting ARV’s
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia
Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Long-Acting Reversible Contraception
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Development of long-acting ARV’s
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia